Torrent Pharmaceuticals said on Wednesday that it has signed an agreement with Boehringer Ingelheim India to jointly market diabetes drugs and their combinations in the country.
The company has signed an agreement to jointly sell Cospiaq (Empagliflozin), Cospiaq Met (Empagliflozin+ Metformin) and Xilingio (Empagliflozin+ Linagliptin).
Empagliflozin is a novel sodium glucose cotransporter-2 (SGLT-2) inhibitor, which is useful for improving glycemic control in adults with type 2 diabetes. diabetes diabetes
It is also indicated to reduce the risk of cardiovascular death, in adults with type 2 diabetes mellitus and established cardiovascular disease.
"I am confident that the launch of Cospiaq, Cospiaq Met and Xilingio will further strengthen our overall diabetes and cardiovascular portfolios and reinforce our position as a leading player in these high-growth segments within the Indian pharmaceutical market," said the director of Torrent Pharmaceuticals. , Aman Mehta, in a statement.
Boehringer Ingelheim India CEO Vani Manja said the company's collaboration with Torrent reaffirms its commitment to enable better access to innovative medicine in India.
According to the International Diabetes Federation, India has the second largest diabetes patient base in the world with an estimated 74.2 million adults (age group 20-79 years) as of 2021. This is expected to increase almost 125 million patients by 2045.
According to AWACS MAT data of October 2022, the Indian diabetes drug market is valued at Rs 16,516 crore, growing at 8.6% CAGR over the past four years.
The SGLT-2 inhibitor market is valued at around Rs 1,927 crore.
(Only the headline and image in this report may have been modified by Business Standard staff; all other content is auto-generated from a syndicated feed.)
